
    
      This is a multicenter, randomized, double-blind, two-arm study to evaluate the safety,
      tolerability, efficacy and PK of the coadministration of SCY-078 plus voriconazole compared
      to those of voriconazole in male and female subjects 18 years of age and older with a
      hematological malignancy (HM) or a myelodysplastic syndrome or aplastic anemia or
      hematopoietic cell transplantation (HCT) and a probable or proven invasive pulmonary
      aspergillosis based on EORTCMSG criteria. In addition, all subjects must be positive (â‰¥0.5)
      for serum GMI.
    
  